Back to top
more

HealthEquity (HQY)

(Real Time Quote from BATS)

$79.25 USD

79.25
94,538

-0.15 (-0.19%)

Updated May 21, 2024 12:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 248)

Industry: Medical Services

Better trading starts here.

Zacks News

Three Reasons to Add DaVita (DVA) Stock to Your Portfolio

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

DexCom (DXCM) Launches Latest CGM Sensor ONE in France

DexCom's (DXCM) latest CGM sensor, DexCom ONE, secures reimbursement coverage in France, bringing the real-time CGM sensor to half a million diabetes patients in the country.

Stryker's (SYK) New Camera Platform to Improve Surgery Outcomes

Stryker's (SYK) latest camera platform is likely to enhance the surgical experience across specialties.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why You Should Retain Fresenius Medical (FMS) for Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Here's Why You Should Retain Cencora (COR) Stock for Now

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Veeva Systems' (VEEV) New Release to Address Supply-Chain Issues

Veeva Systems' (VEEV) new cloud application is likely to improve efficiency and accelerate time-to-market by connecting systems and automating data aggregation, reviews and traceability.

Here's Why You Should Retain DexCom (DXCM) Stock for Now

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations

OPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presentations of long-acting peptides.

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.

Stryker (SYK) Gets FDA 501k Clearance for Pangea Trauma Systems

Stryker's (SYK) Pangea systems will boost the company's Trauma business unit following a complete launch. SYK plans to present the new system at the Annual Orthopaedic Trauma Association meeting.

Surmodics (SRDX) Hits 52-Week High: What's Driving the Stock?

Investors are optimistic about Surmodics' (SRDX) consistent efforts to boost R&D.

DexCom (DXCM) Rises 7% in One Week: What's Driving It?

DexCom's (DXCM) shares have rallied nearly 7% over the past week, presumably on positive outlook for its CGM devices amid rising competition.

Reasons to Retain Baxter International (BAX) in Your Portfolio

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio

Integer Holdings' (ITGR) improving non-medical sales and a solid foothold in the broader MedTech space raise optimism about the stock.

Avantor's (AVTR) Tie-Up to Address Temperature-Specific Logistics

Avantor's (AVTR) partnership is likely to meet the growing need among biopharma and life science companies for end-to-end solutions.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Shopify, Novo Nordisk, Amgen in Focus

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

BD's (BDX) Tie-Up to Explore Flow Cytometry for Clinical Outcomes

BD's (BDX) latest partnership is likely to accelerate the delivery of innovative personalized therapies to patients who need them the most.

Align Technology's (ALGN) New Feature to Boost Patient Experience

Align Technology's (ALGN) introduction of the new SmartForce feature is expected to minimize the number of attachments while maintaining predictable treatment outcomes.

Company News for Sep 7, 2023

Companies In The News Are: AVAv, ASND, HQY, PLAB.

Merit Medical's (MMSI) Aspira Bottle to Boost At-Home Services

Merit Medical (MMSI) launches Aspira Bottle, complementing its Aspira Drainage System, that can provide compassionate home treatment option for critical cancer and other patients.

HealthEquity (HQY) Surpasses Q2 Earnings Estimates, FY24 View Up

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the second quarter of fiscal 2024.

Why You Should Add Surmodics (SRDX) Stock to Your Portfolio

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

Revvity (RVTY) Launches Three New Preclinical Research Systems

Revvity (RVTY) launches new preclinical imaging technologies for breakthrough discoveries. Learn how they can help advance research and boost Revvity's prospect.